RAC - Charts & Price Action, page-10357

some fun facts, checked Su et al 2020 and Zantrene purchased from Sigma-Aldrich. Per Race Ann Oct 2018, manufacture Irisys LLC commenced for sale.

Also Dr Chen FTO funding period is up on 31st March assuming a follow up or final paper may be next on the cards to close out or extend funding.

The 2020 paper was clear on FTO and bisantrene where would Chen take the remaining research? Go more in detail after their patent apps failed or perhaps anti-pd1 resistance or was Su et al it?

Lots of questions today but mostly rhetorical unless you would like to input. Much appreciated great discussions going on and glad they are not about SPP ; )